glp-1 receptor agonists alternatives to ozempic PDB-101: Molecule of the Month: novo nordisk glp-1 receptor agonists
Description
doi:10.1007/s11886-024-02097-4 6
Advances in Experimental Medicine and Biology, 1328, 513-522
Mazdutide has demonstrated remarkably low discontinuation rates (near 1% in early trials) compared to retatrutide (12-18% in Phase 3)
Second-line treatments include basal insulin, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RA), sodiumglucose cotransporter 2 inhibitors (SGLT2-I), sulfonylureas (SU), or thiazolidinediones (TZD)
32(suppl_2)
Jones KL, Rigda RS, Buttfield MDM, et al
